FibroGen (FGEN) Appoints David DeLucia as CFO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
H.C. Wainwright Starts FibroGen (FGEN) at Buy
December 17, 2024 7:57 AM ESTH.C. Wainwright analyst Matt Keller initiates coverage on FibroGen (NASDAQ: FGEN) with a Buy rating and a price target of $10.00.
The analyst comments "FibroGen's ADC pipeline could be a whole new ball game in mCRPC and beyond. We are initiating coverage of FibroGen with a Buy rating and $10 PT. FibroGens lead asset, FG-3246, is a novel antibody drug conjugate (ADC) targeting CD46 expressing tumors.... More
